263 related articles for article (PubMed ID: 37164449)
1. OncoVEX
Estrada J; Zhan J; Mitchell P; Werner J; Beltran PJ; DeVoss J; Qing J; Cooke KS
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37164449
[TBL] [Abstract][Full Text] [Related]
2. Local Delivery of OncoVEX
Moesta AK; Cooke K; Piasecki J; Mitchell P; Rottman JB; Fitzgerald K; Zhan J; Yang B; Le T; Belmontes B; Ikotun OF; Merriam K; Glaus C; Ganley K; Cordover DH; Boden AM; Ponce R; Beers C; Beltran PJ
Clin Cancer Res; 2017 Oct; 23(20):6190-6202. PubMed ID: 28706012
[No Abstract] [Full Text] [Related]
3. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.
Thomas S; Kuncheria L; Roulstone V; Kyula JN; Mansfield D; Bommareddy PK; Smith H; Kaufman HL; Harrington KJ; Coffin RS
J Immunother Cancer; 2019 Aug; 7(1):214. PubMed ID: 31399043
[TBL] [Abstract][Full Text] [Related]
4. Combination immunotherapy including OncoVEX
Gartrell RD; Blake Z; Rizk EM; Perez-Lorenzo R; Weisberg SP; Simoes I; Esancy C; Fu Y; Davari DR; Barker L; Finkel G; Mondal M; Minns HE; Wang SW; Fullerton BT; Lozano F; Chiuzan C; Horst B; Saenger YM
Cancer Immunol Immunother; 2022 Aug; 71(8):1837-1849. PubMed ID: 34999916
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic viral therapy with a combination of HF10, a herpes simplex virus type 1 variant and granulocyte-macrophage colony-stimulating factor for murine ovarian cancer.
Goshima F; Esaki S; Luo C; Kamakura M; Kimura H; Nishiyama Y
Int J Cancer; 2014 Jun; 134(12):2865-77. PubMed ID: 24265099
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival.
Bommareddy PK; Wakimoto H; Martuza RL; Kaufman HL; Rabkin SD; Saha D
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38599661
[TBL] [Abstract][Full Text] [Related]
7. Intratumoral Immunotherapy-Update 2019.
Hamid O; Ismail R; Puzanov I
Oncologist; 2020 Mar; 25(3):e423-e438. PubMed ID: 32162802
[TBL] [Abstract][Full Text] [Related]
8. Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition.
Jennings VA; Scott GB; Rose AMS; Scott KJ; Migneco G; Keller B; Reilly K; Donnelly O; Peach H; Dewar D; Harrington KJ; Pandha H; Samson A; Vile RG; Melcher AA; Errington-Mais F
Mol Ther; 2019 Jun; 27(6):1139-1152. PubMed ID: 31053413
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic virotherapy with an HSV amplicon vector expressing granulocyte-macrophage colony-stimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virus.
Kohno SI; Luo C; Nawa A; Fujimoto Y; Watanabe D; Goshima F; Tsurumi T; Nishiyama Y
Cancer Gene Ther; 2007 Nov; 14(11):918-26. PubMed ID: 17693992
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade.
Ju F; Luo Y; Lin C; Jia X; Xu Z; Tian R; Lin Y; Zhao M; Chang Y; Huang X; Li S; Ren W; Qin Y; Yu M; Jia J; Han J; Luo W; Zhang J; Fu G; Ye X; Huang C; Xia N
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688558
[TBL] [Abstract][Full Text] [Related]
11. The safety of talimogene laherparepvec for the treatment of advanced melanoma.
Gangi A; Zager JS
Expert Opin Drug Saf; 2017 Feb; 16(2):265-269. PubMed ID: 27989216
[TBL] [Abstract][Full Text] [Related]
12. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
Andtbacka RH; Kaufman HL; Collichio F; Amatruda T; Senzer N; Chesney J; Delman KA; Spitler LE; Puzanov I; Agarwala SS; Milhem M; Cranmer L; Curti B; Lewis K; Ross M; Guthrie T; Linette GP; Daniels GA; Harrington K; Middleton MR; Miller WH; Zager JS; Ye Y; Yao B; Li A; Doleman S; VanderWalde A; Gansert J; Coffin RS
J Clin Oncol; 2015 Sep; 33(25):2780-8. PubMed ID: 26014293
[TBL] [Abstract][Full Text] [Related]
13. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma.
Kaufman HL; Kim DW; DeRaffele G; Mitcham J; Coffin RS; Kim-Schulze S
Ann Surg Oncol; 2010 Mar; 17(3):718-30. PubMed ID: 19915919
[TBL] [Abstract][Full Text] [Related]
14. Novel Oncolytic Herpes Simplex Virus 1 VC2 Promotes Long-Lasting, Systemic Anti-melanoma Tumor Immune Responses and Increased Survival in an Immunocompetent B16F10-Derived Mouse Melanoma Model.
Uche IK; Fowlkes N; Vu L; Watanabe T; Carossino M; Nabi R; Del Piero F; Rudd JS; Kousoulas KG; Rider PJF
J Virol; 2021 Jan; 95(3):. PubMed ID: 33177208
[TBL] [Abstract][Full Text] [Related]
15. Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB-IVM1c melanoma.
Malvehy J; Samoylenko I; Schadendorf D; Gutzmer R; Grob JJ; Sacco JJ; Gorski KS; Anderson A; Pickett CA; Liu K; Gogas H
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33785610
[TBL] [Abstract][Full Text] [Related]
16. Prime-boost immunization by both DNA vaccine and oncolytic adenovirus expressing GM-CSF and shRNA of TGF-β2 induces anti-tumor immune activation.
Kim SY; Kang D; Choi HJ; Joo Y; Kim JH; Song JJ
Oncotarget; 2017 Feb; 8(9):15858-15877. PubMed ID: 28178658
[TBL] [Abstract][Full Text] [Related]
17. MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation.
Bommareddy PK; Aspromonte S; Zloza A; Rabkin SD; Kaufman HL
Sci Transl Med; 2018 Dec; 10(471):. PubMed ID: 30541787
[TBL] [Abstract][Full Text] [Related]
18. Talimogene laherparepvec (T-VEC) as cancer immunotherapy.
Kohlhapp FJ; Zloza A; Kaufman HL
Drugs Today (Barc); 2015 Sep; 51(9):549-58. PubMed ID: 26488034
[TBL] [Abstract][Full Text] [Related]
19. Talimogene Laherparepvec for Treating Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Fleeman N; Bagust A; Boland A; Beale S; Richardson M; Krishan A; Stainthorpe A; Abdulla A; Kotas E; Banks L; Payne M
Pharmacoeconomics; 2017 Oct; 35(10):1035-1046. PubMed ID: 28316007
[TBL] [Abstract][Full Text] [Related]
20. Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma.
Ferrucci PF; Pala L; Conforti F; Cocorocchio E
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33803762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
